Saturday, October 5, 2024
    -Advertisement-

    Argentina authorizes emergency use of Chinese Sinopharm vaccine

    The Argentine government has officially approved the emergency use of an inactivated COVID-19 vaccine developed by Chinese pharmaceutical company Sinopharm, according to a resolution signed by the minister on Sunday. of Health Carla Vizzotti.

    The resolution was signed by Ms. Vizzotti after the National Administration of Drugs, Food and Medical Technologies (ANMAT) advised the Ministry of Health to include Sinopharm’s vaccine in the national COVID vaccination plan. 19.

    - Advertisement -

    The minister’s spokesperson stressed that clinical trials of the vaccine have shown it to be “safe and effective”.

    Sinopharm’s vaccine is the fifth authorized by Argentina, after that of Pfizer-BioNTech, Russian Sputnik V, Swedish-British AstraZeneca, and Covishield produced by the Serum Institute of India.

    - Advertisement -

    According to President Alberto Fernandez’s social media account, “more than 700,000 people have received doses of the COVID-19 vaccine and more than 400,000 people have already received both doses” (and are therefore immune).

    “The vaccination rate will accelerate with the arrival of more vaccines in the country,” Fernandez said.

    The South American country has recorded a total of 2,064,334 cases and 51,198 deaths, as of Sunday evening.


    Discover more from MegaloPreneur Magazine

    Subscribe to get the latest posts sent to your email.

    - Advertisement -

    For the latest updates and news, follow The MegaloPreneur Magazine on Google News. To show your support for The MegaloPreneur Magazine, click here.

    Pat Wallace
    Pat Wallace
    Author at Megalopreneur Magazine: Unveiling trends, unraveling technology stories, and elevating brands to new heights through insightful and compelling tech narratives that shape the future.

    Discover more from MegaloPreneur Magazine

    Subscribe now to keep reading and get access to the full archive.

    Continue reading